Variety of suitable people: CDEC reviewed the uncertainty in the number of sufferers with moderately significant to critical hemophilia B in Canada eligible for etranacogene dezaparvovec. Medical experts consulted by CADTH indicated that some clients who are categorised as getting moderate or moderate disease can have a intense bleeding phenotype,